市场概况：
TheUnited States diabetes market在2019年达到494亿美元的价值。展望未来，IMARC Group预计该市场将在2020 - 2025年期间展现出适度欧宝电竞首页的增长。考虑到Covid-19的不确定性，我们一直在不断跟踪和评估流行对不同最终用途行业的直接和间接影响。OB欧宝体育这些见解作为主要市场贡献者包含在报告中。
Diabetes, also referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. This can be either caused by the inappropriate response to insulin by the body, inadequate insulin production. If not monitored properly, diabetes can be fatal and cause serious health complications such as heart diseases, stroke, amputation, blindness and kidney diseases. According to the Centers for Disease Control and Prevention (CDC), more than 30 million adults have been diagnosed with diabetes or prediabetes in the United States. In 2018, the United States represented the third largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels. Apart from this, physical inactivity and unhealthy lifestyle have further contributed to the escalating diabetic population.
糖尿病患病率增加了政府ernment of US to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In line with this, there has been a rise in diabetes diagnosis, monitoring and drug treatment rates. Moreover, the FDA has approved the production of Basaglar and Admelog, the biosimilar versions of insulin glargine and lispro. Several other diabetes drugs are also expected to gain approval in the coming years, which will further drive the growth of the market. Apart from this, rapid technological advancements have enabled the manufacturers to develop continuous glucose monitoring (CGM) device. It allows type-2 diabetes patients to check their blood periodically with the help of testing strips and easily monitor their blood sugar levels.
关键市场细分：
IMARC Group provides an analysis of the key trends in each sub-segment of the United States diabetes market, along with forecasts from 2020-2025. Our report has categorized the market based on segment.
按细分细分分手：
目前，由于胰岛素递送设备的便利性和功效，胰岛素在口服抗糖尿病中表现出明显的优势。在各种产品类型中，长作用胰岛素代表了美国最大的胰岛素类别，而DPP-IV抑制剂是美国领先的口腔抗抗糖尿病类别。
竞争格局：
The report has examined the competitive landscape of the market and finds that it is highly fragmented in nature with the presence of numerous small and large manufacturers. Some of the key players operating in the market are:
- 赛诺菲美国服务公司
- Novo Nordisk Inc.
- Eli Lilly and Company
- Merck & Co. Inc.
- Zeneca Holdings Inc.
- Johnson & Johnson
我们在本报告中所取得的成就：
美国糖尿病流行病学及其动态的全面情况分析：
Focus of the Analysis:
- 美国糖尿病的历史，当前和未来患病率
- Impact of COVID-19 on the diabetes market in the United States
- 美国1型和2型糖尿病的历史，当前和未来患病率
- Historical, current and future prevalence of diabetes in the urban and rural regions in the US
- Historical, current and future prevalence of diabetes among males and females in the US
- Historical, current and future prevalence of diabetes among various age groups in the US
- Historical, current and future diagnosis rates for diabetes in the US
- Historical, current and future drug treatment rates for diabetes in the US
Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
- Performance of the Oral Antidiabetics market in the US
- Performance of key classes
- Performance of key players
- Market outlook
Comprehensive situation analysis of the US Insulin market and its dynamics:
Focus of the Analysis:
- Performance of the Insulin market in the US
- Performance of key classes
- Performance of key players
- Market outlook
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1主要来源
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2自上而下的方法
2.5预测方法
3执行摘要
4 Introduction
4.1概述
4.2 Key Industry Trends
5 Diabetes Disease Overview
5.1什么是糖尿病？
5.2糖尿病诊断和治疗
5.2.1 Diagnosis
5.2.2治疗
5.3 Diabetes Complications
6 US Diabetes Epidemiology
6.1糖尿病人口和患病率
6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
6.3人口和划分地区的患病率
6.4 Population and Prevalence Rates by Gender
6.5 Population and Prevalence Rates by Age Group
7 US Diabetes Market
7.1 Market Overview
7.2 Market Performance
7.3 Impact of COVID-19
7.4 Market Forecast
7.5 SWOT Analysis
7.5.1概述
7.5.2 Strengths
7.5.3弱点
7.5.4 Opportunities
7.5.5 Threats
7.6价值链分析
7.7波特的五力量分析
7.7.1概述
7.7.2 Bargaining Power of Buyers
7.7.3 Bargaining Power of Suppliers
7.7.4 Degree of Competition
7.7.5新进入者的威胁
7.7.6 Threat of Substitutes
7.8按细分市场破裂
7.8.1美国口服抗糖尿病市场
7.8.1.1 Historical Market Trends
7.8.1.2 Market Breakup by Class
7.8.1.3主要参与者的市场份额
7.8.1.4 Market Forecast
7.8.2 US Insulin Market
7.8.2.1历史市场趋势
7.8.2.2按课程分手
7.8.2.3主要参与者的市场份额
7.8.2.4市场预测
8 Competitive Landscape
8.1 Competitive Structure
8.2主要参与者
8.3 Profiles of Key Players
List of Figures
Figure 1: The Impact of Diabetes in the Human Body
图2：糖尿病并发症
图3：全球：按地区分解糖尿病患者，（in％）2019和2025
Figure 4: US: Overweight & Obese Population (in Million), 2014, 2019 & 2025
图5：体重指数和2型糖尿病的相对风险
图6：美国：按年龄组分解总人口（0-14、15-64＆65+，％），2019年
Figure 7: US: Diabetes Prevalence by Age Groups (in %), 2019
Figure 8: US: Total Number of Diabetes Patients (in ‘000), 2014-2019
Figure 9: US: Total Number of Diabetes Patients Forecast (in ‘000), 2020-2025
图10：US（Type1＆Type2）：糖尿病患者总数（000），2014- 2019年
图11：US（Type1＆Type2）：糖尿病患者总数（000），2020-2025
Figure 12: US (Urban & Rural): Total Number of Diabetes Patients (in 000), 2014-2019
图13：美国（Urban＆Rural）：糖尿病患者总数（000），2020-2025
图14：美国（男性和女性）：糖尿病患者总数（000），2014- 2019年
Figure 15: US (Male & Female): Total Number of Diabetes Patients (in 000), 2020-2025
图16：美国：按年龄组按糖尿病患者的总数（20-39、40-59和60-79，in 000），2014- 2019年
Figure 17: US: Total Number of Diabetes Patients by Age Group (20-39, 40-59 & 60-79, in ‘000), 2020-2025
图18：美国：糖尿病制药行业概述
Figure 19: US: Diabetes Drug Market: Sales Value (in Million US$), 2014-2019
Figure 20: US: Diabetes Drug Market Forecast: Sales Value (in Million US$), 2020-2025
Figure 21: US: Diabetes Drug Market: SWOT Analysis
图22：美国：糖尿病药物市场：价值链分析
Figure 23: US: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: US: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2014-2019
Figure 25: US: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2020-2025
Figure 26: US: Oral Antidiabetics Market: Sales Value (in Million US$), 2014-2019
Figure 27: US: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2014 & 2019
Figure 28: US: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
图29：美国：口服抗糖尿病市场：销售价值（百万美元），2020-2025
Figure 30: US: Insulin Market, (in Million US$), 2014-2019
图31：美国：胰岛素市场按班级分解（百分比），2019年
Figure 32: US: Insulin Market: Sales Share of Key Players (in %)
Figure 33: US: Insulin Market Forecast: Sales Value (in Million US$), 2020-2025
List of Tables
表1：糖尿病的诊断
表2：全球：按国家 /地区（000年代）的糖尿病人口分手，2019年和2025年
表3:我们结束了weight & Obesity Statistics, 2014, 2019 & 2025
Table 4: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+, in Million)
表5：美国：糖尿病患者的总患病率和数量（'000），2014，2019＆2025
Table 6: US (Type1 & Type2): Total Prevalence & Number of Diabetes Patients (in ‘000), 2014, 2019 & 2025
Table 7: US (Urban & Rural): Total Prevalence & Number of Diabetes Patients (in ‘000), 2014, 2019 & 2025
Table 8: US (Male & Female): Total Prevalence & Number of Diabetes Patients (in ‘000), 2014, 2019 & 2025
表9：美国：按年龄组按年龄组的总患病率和糖尿病患者人数（20-39、40-59＆60-79，in'000），2014年，2019年和2025
Table 10: US: Diabetes Drug Market: Competitive Structure
Table 11: US: Diabetes Drug Market: Key Players